Yark Hazewinkel1, Kristien M A J Tytgat1, Monique E van Leerdam2, Jan-Jacob Koornstra3, Barbara A Bastiaansen1, Susanne van Eeden4, Paul Fockens1, Evelien Dekker1. 1. Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, the Netherlands. 2. Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, the Netherlands and Department of Gastroenterology and Hepatology, Netherlands Cancer Institute, Amsterdam, the Netherlands. 3. Department of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, the Netherlands. 4. Department of Pathology, Academic Medical Center, Amsterdam, the Netherlands.
Abstract
BACKGROUND: Serrated polyposis syndrome (SPS) is characterized by the presence of multiple serrated polyps spread throughout the colon. Patients with SPS are considered to be at risk of colorectal cancer and are advised to undergo endoscopic surveillance. Narrow-band imaging (NBI) may improve the detection of polyps during these surveillance colonoscopies. OBJECTIVE: To compare polyp miss rates between NBI and high-resolution white-light endoscopy (HR-WLE). DESIGN: Multicenter, randomized, crossover study. SETTING: Four tertiary referral institutions. PATIENTS: A total of 52 patients with SPS undergoing surveillance colonoscopy. INTERVENTION: All patients underwent back-to-back colonoscopies with HR-WLE and NBI in a randomized order. MAIN OUTCOME MEASUREMENTS: Polyp miss rates of HR-WLE and NBI. RESULTS: In the HR-WLE group, 116 polyps were detected during the first inspection. A second inspection with NBI added 47 polyps, resulting in an overall polyp miss rate of 29% with HR-WLE (95% confidence interval, 22-36). In the NBI group, a total of 128 polyps were detected during the first inspection. Subsequent inspection with HR-WLE added 32 polyps, resulting in an overall polyp miss rate of NBI of 20% (95% confidence interval, 15-27). Comparison of the overall polyp miss rates of HR-WLE and NBI showed no significant difference (P = .065). LIMITATIONS: Small sample size; second inspection was performed by the same endoscopist. CONCLUSIONS: The results of our study suggest that NBI does not reduce polyp miss rates in patients with SPS compared with HR-WLE. Further multinational studies with larger numbers of patients are warranted to verify these results. ( CLINICAL TRIAL REGISTRATION NUMBER: NTR2497.).
RCT Entities:
BACKGROUND: Serrated polyposis syndrome (SPS) is characterized by the presence of multiple serrated polyps spread throughout the colon. Patients with SPS are considered to be at risk of colorectal cancer and are advised to undergo endoscopic surveillance. Narrow-band imaging (NBI) may improve the detection of polyps during these surveillance colonoscopies. OBJECTIVE: To compare polyp miss rates between NBI and high-resolution white-light endoscopy (HR-WLE). DESIGN: Multicenter, randomized, crossover study. SETTING: Four tertiary referral institutions. PATIENTS: A total of 52 patients with SPS undergoing surveillance colonoscopy. INTERVENTION: All patients underwent back-to-back colonoscopies with HR-WLE and NBI in a randomized order. MAIN OUTCOME MEASUREMENTS: Polyp miss rates of HR-WLE and NBI. RESULTS: In the HR-WLE group, 116 polyps were detected during the first inspection. A second inspection with NBI added 47 polyps, resulting in an overall polyp miss rate of 29% with HR-WLE (95% confidence interval, 22-36). In the NBI group, a total of 128 polyps were detected during the first inspection. Subsequent inspection with HR-WLE added 32 polyps, resulting in an overall polyp miss rate of NBI of 20% (95% confidence interval, 15-27). Comparison of the overall polyp miss rates of HR-WLE and NBI showed no significant difference (P = .065). LIMITATIONS: Small sample size; second inspection was performed by the same endoscopist. CONCLUSIONS: The results of our study suggest that NBI does not reduce polyp miss rates in patients with SPS compared with HR-WLE. Further multinational studies with larger numbers of patients are warranted to verify these results. ( CLINICAL TRIAL REGISTRATION NUMBER: NTR2497.).
Authors: Elmire Hartmans; Veronique Orian-Rousseau; Alexandra Matzke-Ogi; Arend Karrenbeld; Derk Jan A de Groot; Steven de Jong; Gooitzen M van Dam; Rudolf S N Fehrmann; Wouter B Nagengast Journal: Theranostics Date: 2017-01-06 Impact factor: 11.556
Authors: James E East; Wendy S Atkin; Adrian C Bateman; Susan K Clark; Sunil Dolwani; Shara N Ket; Simon J Leedham; Perminder S Phull; Matt D Rutter; Neil A Shepherd; Ian Tomlinson; Colin J Rees Journal: Gut Date: 2017-04-27 Impact factor: 23.059
Authors: Dominic Staudenmann; Ken Liu; Poornima Varma; May Wong; Sonam Rai; Tatiana Tsoutsman; Kyung Ho Choi; Payal Saxena; Arthur John Kaffes Journal: DEN open Date: 2021-09-01
Authors: Martin Bürger; Marko Weber; Iver Petersen; Andreas Stallmach; Carsten Schmidt Journal: Medicine (Baltimore) Date: 2022-08-12 Impact factor: 1.817
Authors: Peter Klare; Henrik Phlipsen; Bernhard Haller; Henrik Einwächter; Andreas Weber; Mohamed Abdelhafez; Monther Bajbouj; Hayley Brown; Roland M Schmid; Stefan von Delius Journal: Endosc Int Open Date: 2017-12-06